Health
New Drug Shows Promise in Treating Alzheimer’s Symptoms in Mice
A compound derived from common herbs has shown promising results in improving memory and reducing harmful brain protein build-ups in mice, potentially paving the way for new Alzheimer’s treatments.
Breakthrough Study on Memory Enhancement
Researchers from The Scripps Research Institute in the United States have successfully tested a derivative of carnosic acid, a molecule found in rosemary and sage, for its potential in treating Alzheimer’s disease. Their findings, published in the journal Antioxidants, suggest that the compound, called diAcCA, could play a crucial role in combating cognitive decline.
In their study, mice genetically modified to exhibit Alzheimer’s-like symptoms were treated with diAcCA for three months. The results were striking: the mice demonstrated significant improvements in learning and memory, along with an increase in synapses—the vital junctions where neurons communicate. Since synapse loss is strongly linked to cognitive decline, these findings indicate a potential breakthrough in Alzheimer’s research.
Reduction of Alzheimer’s Hallmarks
Beyond cognitive improvements, the treated mice exhibited a reduction in amyloid plaques and tau tangles—two harmful proteins associated with Alzheimer’s. These protein accumulations are key indicators of the disease in humans and contribute to the progressive cognitive deterioration seen in patients.
Professor Stuart Lipton, a senior author of the study, highlighted the dual benefits of diAcCA, stating, “By combating inflammation and oxidative stress, we actually increased the number of synapses in the brain. We also reduced the levels of misfolded or aggregated proteins such as phosphorylated tau and amyloid-β, which are known biomarkers of Alzheimer’s disease.”
An Innovative Approach with Antioxidant Properties
Carnosic acid, the parent molecule of diAcCA, is known for its antioxidant and anti-inflammatory properties. However, it degrades rapidly, making it difficult to use in medical applications. The researchers overcame this limitation by developing diAcCA, a more stable form of the compound that can be taken orally and converted into carnosic acid in the stomach before entering the bloodstream.
According to the study, the amount of the active compound in the blood of treated mice was 20% higher compared to traditional carnosic acid ingestion, suggesting greater efficacy. “We did multiple different tests of memory, and they were all improved with the drug,” Lipton noted. “It didn’t just slow down the decline; it improved virtually back to normal.”
Potential Implications for Alzheimer’s Treatment
Alzheimer’s disease is the most common form of dementia, accounting for 70% of cases. Currently affecting around 7 million people across Europe, this number is expected to double to 14 million by 2030 due to the ageing population.
With promising preclinical results, researchers hope that diAcCA could lead to a viable treatment for Alzheimer’s in humans. The next steps will involve further studies to confirm its effectiveness and safety before progressing to human trials. If successful, this research could mark a significant milestone in the fight against neurodegenerative diseases.
-
Entertainment2 years agoMeta Acquires Tilda Swinton VR Doc ‘Impulse: Playing With Reality’
-
Business2 years agoSaudi Arabia’s Model for Sustainable Aviation Practices
-
Business2 years agoRecent Developments in Small Business Taxes
-
Sports2 years agoChina’s Historic Olympic Victory Sparks National Pride Amid Controversy
-
Home Improvement1 year agoEffective Drain Cleaning: A Key to a Healthy Plumbing System
-
Politics2 years agoWho was Ebrahim Raisi and his status in Iranian Politics?
-
Sports2 years agoKeely Hodgkinson Wins Britain’s First Athletics Gold at Paris Olympics in 800m
-
Business2 years agoCarrectly: Revolutionizing Car Care in Chicago
